Compare Stocks: ADAG, OCS, ALLO, and CRMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$3.64 +0.3%	$3.77	$1.30 ▼ $4.85	$172.50M	0.58	229,179 shs	113,185 shs
ALLO Allogene Therapeutics	$1.90 +3.3%	$1.97	$0.98 ▼ $4.46	$655.79M	0.48	8.41 million shs	5.00 million shs
CRMD CorMedix	$7.53 -0.3%	$8.30	$6.13 ▼ $14.96	$590.73M	1.5	1.73 million shs	651,049 shs
OCS Oculis	$11.99 +0.8%	$13.43	$10.52 ▼ $34.47	$695.23M	0.44	488,596 shs	310,990 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-3.20%	+2.83%	-18.79%	+0.28%	+89.06%
ALLO Allogene Therapeutics	-2.13%	+5.14%	-11.54%	-15.21%	+70.37%
CRMD CorMedix	+0.27%	-0.66%	-13.71%	-2.33%	-35.14%
OCS Oculis	+5.13%	+7.89%	-15.79%	-57.15%	-32.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$3.64 +0.3%	$3.77	$1.30 ▼ $4.85	$172.50M	0.58	229,179 shs	113,185 shs
ALLO Allogene Therapeutics	$1.90 +3.3%	$1.97	$0.98 ▼ $4.46	$655.79M	0.48	8.41 million shs	5.00 million shs
CRMD CorMedix	$7.53 -0.3%	$8.30	$6.13 ▼ $14.96	$590.73M	1.5	1.73 million shs	651,049 shs
OCS Oculis	$11.99 +0.8%	$13.43	$10.52 ▼ $34.47	$695.23M	0.44	488,596 shs	310,990 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-3.20%	+2.83%	-18.79%	+0.28%	+89.06%
ALLO Allogene Therapeutics	-2.13%	+5.14%	-11.54%	-15.21%	+70.37%
CRMD CorMedix	+0.27%	-0.66%	-13.71%	-2.33%	-35.14%
OCS Oculis	+5.13%	+7.89%	-15.79%	-57.15%	-32.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$8.00	119.78% Upside
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.52	348.54% Upside
CRMD CorMedix	2.75	Moderate Buy	$14.86	97.31% Upside
OCS Oculis	2.80	Moderate Buy	$38.33	219.71% Upside

Current Analyst Ratings Breakdown

Latest ADAG, OCS, ALLO, and CRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ADAG Adagene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	OCS Oculis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ADAG Adagene	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
7/7/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$14.00 ➝ $13.00
6/11/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/3/2026	OCS Oculis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$42.00 ➝ $23.00
6/1/2026	OCS Oculis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$49.00 ➝ $38.00
6/1/2026	OCS Oculis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $40.00
6/1/2026	OCS Oculis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$75.00 ➝ $45.00
6/1/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$47.00 ➝ $26.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$7.67M	22.49	N/A	N/A	$0.75 per share	4.85
ALLO Allogene Therapeutics	$20K	32,789.25	N/A	N/A	$1.30 per share	1.46
CRMD CorMedix	$311.71M	1.90	$2.05 per share	3.68	$5.14 per share	1.46
OCS Oculis	N/A	N/A	N/A	N/A	$4.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$17.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
ALLO Allogene Therapeutics	-$190.89M	-$0.77	N/A	N/A	N/A	N/A	-56.45%	-40.36%	8/12/2026 (Estimated)
CRMD CorMedix	$163.05M	$2.13	3.54	753.00	N/A	45.25%	45.57%	24.76%	8/13/2026 (Estimated)
OCS Oculis	-$119.44M	-$2.13	N/A	N/A	N/A	-8,460.67%	-56.78%	-45.62%	8/6/2026 (Estimated)

Latest ADAG, OCS, ALLO, and CRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRMD CorMedix	$0.26	N/A	N/A	N/A	$96.04 million	N/A
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.16	N/A	N/A	N/A	$0.00 million	N/A
8/6/2026	Q2 2026	OCS Oculis	-$0.48	N/A	N/A	N/A	$0.23 million	N/A
5/14/2026	Q1 2026	CRMD CorMedix	$0.35	$0.43	+$0.08	$0.43	$104.96 million	$127.43 million
5/13/2026	Q1 2026	ALLO Allogene Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	$0.00 million	N/A
5/8/2026	Q1 2026	OCS Oculis	-$0.49	-$0.63	-$0.14	-$0.61	$0.25 million	$0.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.03	3.07	3.07
ALLO Allogene Therapeutics	N/A	9.65	9.65
CRMD CorMedix	0.33	2.97	2.74
OCS Oculis	0.01	5.18	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
ALLO Allogene Therapeutics	83.63%
CRMD CorMedix	34.18%
OCS Oculis	22.30%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
ALLO Allogene Therapeutics	13.20%
CRMD CorMedix	3.50%
OCS Oculis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.39 million	37.34 million	Not Optionable
ALLO Allogene Therapeutics	310	345.15 million	299.60 million	Optionable
CRMD CorMedix	30	78.45 million	75.71 million	Optionable
OCS Oculis	2	57.98 million	N/A	Not Optionable

ADAG, OCS, ALLO, and CRMD Headlines

Recent News About These Companies

Oculis Holding AG (NASDAQ:OCS) Receives $38.33 Consensus PT from Analysts

August 4 at 3:59 AM | americanbankingnews.com

Oculis (NASDAQ:OCS) Shares Gap Up - Time to Buy?

August 3 at 12:39 PM | marketbeat.com

Oculis Receives Positive FDA Feedback Supporting Development Pathway for Privosegtor in Acute Multiple Sclerosis Relapses

August 3 at 4:10 AM | quiverquant.comQ

Oculis Receives Positive FDA Feedback for Privosegtor Development in Acute Multiple Sclerosis Relapses

August 3 at 4:10 AM | quiverquant.comQ

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

August 3 at 4:00 AM | globenewswire.com

Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts

July 30, 2026 | marketbeat.com

Oculis (OCS) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

OCS Group to buy Mitie for $4.17 billion

July 21, 2026 | reuters.com

Oculis (NASDAQ:OCS) Lowered to "Strong Sell" Rating by Wall Street Zen

July 12, 2026 | marketbeat.com

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

July 8, 2026 | globenewswire.com

Oculis to Present Late-Stage Pipeline Update at Piper Sandler Virtual Ophthalmology Conference

July 2, 2026 | quiverquant.comQ

Oculis to Participate in Piper Sandler Virtual Ophthalmology Conference Fireside Chat

July 2, 2026 | quiverquant.comQ

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

July 2, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 25, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 23, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 18, 2026 | prnewswire.com

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

June 17, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 16, 2026 | globenewswire.com

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

June 11, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 11, 2026 | prnewswire.com

Oculis Holding AG to Present Privosegtor Development at Clinical Trials at the Summit 2026

June 11, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADAG, OCS, ALLO, and CRMD Company Descriptions

Adagene NASDAQ:ADAG

$3.64 +0.01 (+0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$3.65 +0.01 (+0.27%)

As of 04:10 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Allogene Therapeutics NASDAQ:ALLO

$1.90 +0.06 (+3.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.90 +0.01 (+0.26%)

As of 05:02 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

CorMedix NASDAQ:CRMD

$7.53 -0.02 (-0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$7.50 -0.03 (-0.40%)

As of 05:14 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Oculis NASDAQ:OCS

$11.99 +0.10 (+0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$11.94 -0.05 (-0.42%)

As of 04:36 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAG, OCS, ALLO, and CRMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAG, OCS, ALLO, and CRMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAG, OCS, ALLO, and CRMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADAG, OCS, ALLO, and CRMD Company Descriptions

Adagene NASDAQ:ADAG

Allogene Therapeutics NASDAQ:ALLO

CorMedix NASDAQ:CRMD

Oculis NASDAQ:OCS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAG, OCS, ALLO, and CRMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAG, OCS, ALLO, and CRMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAG, OCS, ALLO, and CRMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADAG, OCS, ALLO, and CRMD Company Descriptions

Adagene NASDAQ:ADAG

Allogene Therapeutics NASDAQ:ALLO

CorMedix NASDAQ:CRMD

Oculis NASDAQ:OCS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools